Cargando…
Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges
The field of oncolytic virotherapy has seen remarkable advancements in last two decades, leading to approval of the first oncolytic immuno-virotherapy, Talimogene Laherparepvec, for the treatment of melanoma. A plethora of preclinical and clinical studies have demonstrated excellent safety profiles...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352900/ https://www.ncbi.nlm.nih.gov/pubmed/32604787 http://dx.doi.org/10.3390/cancers12061699 |